...
首页> 外文期刊>Arthritis research & therapy. >Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs
【24h】

Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs

机译:评估用于启动抗风湿药物的患者决策辅助工具的评估

获取原文
           

摘要

Background According to international guidelines, treatment of inflammatory arthritis should be based on a shared decision between patient and rheumatologist. Furthermore, patients with inflammatory arthritis have high need of information and want to be more actively involved in medical decision-making. To facilitate shared decision-making and support patients in choosing between disease modifying anti-rheumatic drugs (DMARDs), a web-based patient decision aid (PtDA) was developed. This study evaluated use, appreciation and effect of this PtDA. Methods A post-test only study with a historical comparison group was conducted. In a two-year period, all patients diagnosed with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis, who were deciding whether to start a (different) DMARD were invited to participate. In the first year, patients received standard information (comparison group). In the second year, patients were referred to the PtDA (intervention group). In both groups, a questionnaire was sent four weeks after consulting the rheumatologist. Patient characteristics included sociodemographic, health-related and preference-related variables. Process measures were for use and appraisal of the PtDA (intervention group only). The primary outcome measure was patients’ perceived role in medical decision-making. Secondary outcome measures comprised satisfaction with the decision-making process and the decision, beliefs about medication, adherence to medication and trust in the physician. Results We received 158/232 questionnaires (68?%) from the comparison group and 123/200 (61?%) from the intervention group. The PtDA was used by 69/123 patients (57?%) in the intervention group. Patients who used the PtDA highly appreciated it and perceived it as easy to use and helpful. Relative to the comparison group, patients in the intervention group perceived a more active role in medical decision-making and decisions were more in line with patients’ personal preferences. Other outcomes showed no significant difference between the two groups. Conclusion The web-based PtDA was highly appreciated and perceived as helpful for decision-making. Implementation of the PtDA in rheumatology practice was associated with a significantly larger proportion of patients perceiving an active role in medical decision-making and decisions were more in line with patients’ personal preferences. The PtDA can be a valuable aid in improving patient participation in decision-making about DMARDs.
机译:背景技术根据国际准则,炎性关节炎的治疗应基于患者和风湿病医师之间的共同决定。此外,炎性关节炎患者对信息的需求很高,并希望更积极地参与医疗决策。为了促进共同的决策制定并支持患者在疾病抗风湿药(DMARD)之间进行选择,开发了基于Web的患者决策辅助工具(PtDA)。这项研究评估了该PtDA的使用,欣赏和效果。方法与历史比较组进行仅测试后的研究。在两年的时间内,所有被诊断患有类风湿性关节炎,牛皮癣性关节炎或强直性脊柱炎的患者都在决定是否开始(不同的)DMARD。在第一年,患者接受了标准信息(比较组)。在第二年,将患者转诊至PtDA(干预组)。在两组中,在咨询风湿病专家四周后都发送了一份问卷。患者特征包括社会人口统计学,健康相关和偏爱相关的变量。工艺措施用于PtDA的使用和评估(仅干预组)。主要结果指标是患者在医疗决策中的感知作用。次要结果指标包括对决策过程和决策的满意度,对药物的信念,对药物的依从性以及对医生的信任度。结果我们从比较组收到了158/232个问卷(68%),从干预组收到了123/200个(61%)。干预组中有69/123名患者(57%)使用了PtDA。使用PtDA的患者高度赞赏它,并认为它易于使用且很有帮助。相对于对照组,干预组的患者在医疗决策中的作用更为积极,决策更符合患者的个人喜好。其他结果显示两组之间无显着差异。结论基于Web的PtDA受到高度赞赏,并被认为有助于决策。 PtDA在风湿病学实践中的实施与在医疗决策中发挥积极作用的患者比例显着增加有关,并且决策更符合患者的个人喜好。 PtDA可以在改善患者参与DMARD决策方面提供宝贵的帮助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号